openPR Logo
Press release

RNAi Therapeutics Market Worth USD 20.35 Bn by 2030 | Quark Software, Roche, Rexahn, Silence Therapeutics

02-21-2024 06:46 AM CET | Health & Medicine

Press release from: Congruence Market Insights

Global RNAi Therapeutics Market, 2023 - 2030

Global RNAi Therapeutics Market, 2023 - 2030

The latest report by Congruence Market Insights, titled 'Global RNAi Therapeutics Market - Size, Trends, Share, Growth, Dynamics, Competition, and Opportunity Forecast, 2023 - 2030,' provides a thorough analysis of the global RNAi therapeutics market. The report meticulously examines both macro and micro trends, offering insights into the dynamic factors influencing the market. It encompasses a detailed exploration of qualitative and quantitative aspects, delivering a precise depiction of market size, growth rates, annual progression, prevailing trends, key drivers, promising opportunities, and potential challenges. Additionally, the report highlights the impact of crucial events such as advancements in RNAi technology and increasing investments in genetic medicine on the RNAi therapeutics market landscape. This exhaustive examination equips businesses and stakeholders with invaluable intelligence for making informed decisions in the evolving RNAi therapeutics industry.

Request full report sample here: https://www.congruencemarketinsights.com/report/rnai-therapeutics-market?section=Request

What is the anticipated market size in 2030, along with the major drivers, restraints, and opportunities?

According to the in-depth market study, the global RNAi therapeutics market is anticipated to reach a value of USD 20.35 Billion by 2030, expanding at a notable CAGR of 8.4% between 2023 and 2030. The RNAi therapeutics market is primarily driven by advancements in RNA interference (RNAi) technology, increasing prevalence of genetic disorders and chronic diseases, and growing demand for personalized medicine. Opportunities lie in expanding applications of RNAi therapeutics in oncology, neurodegenerative disorders, and infectious diseases, as well as the development of novel RNAi delivery systems. However, challenges include off-target effects and the need for further research to enhance RNAi specificity and efficacy.

How does AI impact the global RNAi Therapeutics market?

AI impacts the global RNAi therapeutics market by facilitating drug discovery and development, optimizing treatment strategies, and accelerating personalized medicine initiatives. AI-driven algorithms analyze vast amounts of genomic and clinical data to identify potential RNAi drug targets and predict therapeutic responses, streamlining the drug discovery process and reducing development timelines. Advanced AI models enable personalized treatment approaches by integrating patient-specific genetic information and clinical data, optimizing treatment regimens and improving patient outcomes. Additionally, AI-powered bioinformatics tools facilitate RNAi off-target prediction and design of RNAi delivery vehicles, enhancing the specificity and efficacy of RNAi therapeutics. While AI integration offers significant benefits, challenges include data privacy concerns and the need for regulatory frameworks to govern AI-driven healthcare solutions effectively.

Buy Now @ https://www.congruencemarketinsights.com/buy-now/241/1

Scope of the Report:

► Executive Summary
► Demand and Supply-side Trends
► Market Drivers, Restraints, Opportunities and Challenges
► Value Chain Analysis
► Porter's Five Forces Analysis
► Industry SWOT Analysis
► COVID-19 Impact Assessment
► PESTLE Analysis
► Global Market Size and Forecast
► Regional Market Size and Forecast (Cross-country Analysis)
► Competition Landscape
► Company Profiles

RNAi Therapeutics Market Size and Forecast:

The report will comprehensively detail the RNAi therapeutics market size and forecast (2023-2030), presenting key metrics for strategic insights. We will analyze market revenue, quantifying total income from RNAi therapeutics sales, and provide volume insights into product circulation. The report will delineate market share, highlighting competitive landscapes. Year-on-Year growth analysis will track annual percentage changes, offering trend insights. Additionally, the Compound Annual Growth Rate (CAGR) will be presented, providing a smoothed growth rate for a more consistent assessment of the market's expansion over the forecast period.

Which region holds the largest market share, and where does the major opportunity lie in the future?

North America holds the largest market share in the global RNAi therapeutics market, driven by a robust biotechnology and pharmaceutical industry, significant investments in genomic medicine, and a high prevalence of genetic disorders and chronic diseases. Major opportunities lie in expanding applications of RNAi therapeutics in precision medicine and developing targeted therapies for rare diseases. Additionally, Europe and Asia Pacific are expected to witness significant growth opportunities due to increasing government initiatives to promote genetic medicine research and development, rising healthcare expenditure, and growing adoption of personalized medicine approaches.

Competition Landscape

The global RNAi therapeutics market is highly competitive, characterized by the presence of established pharmaceutical companies and biotechnology firms, as well as innovative startups focusing on RNAi drug development. Key competitors focus on research and development of novel RNAi therapeutics targeting various disease indications, strategic collaborations, and acquisitions to expand their product portfolios and strengthen their market position. Diverse applications, ranging from genetic disorders to oncology and infectious diseases, contribute to market dynamism. The competition landscape is shaped by a blend of industry incumbents and emerging players, all vying for leadership in this rapidly evolving segment of the biopharmaceutical industry.

>> Quark Software Inc.
>> F. Hoffmann-La Roche Ltd.
>> Rexahn Pharmaceuticals, Inc.
>> Silence Therapeutics
>> Arbutus Biopharma
>> Benitec Biopharma
>> GSK plc
>> OLIX PHARMACEUTICALS, INC.
>> Sanofi
>> Alnylam Pharmaceuticals, Inc.
>> Moderna Inc.
>> Ionis Pharmaceuticals

Comprehensive Market Segmentation:

∆ By Molecule Type (Small Interfering RNAS, Microrna)
∆ By Application (Genetic Disorder, Oncology, Neurodegenerative Disorder, Cardiovascular Disorder, Respiratory Disorder, Infectious Disease, Renal Disease, Other)
∆ By Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, Others)
∆ By End- User (Diagnostic Laboratories, Research and Academic Laboratories, Hospitals)

Market Segmentation by Geography including:

∆ North America: U.S., Canada and Mexico
∆ Europe: Germany, France, U.K., Italy, Spain, and Rest of Europe
∆ Asia Pacific: China, India, Japan, South Korea, Southeast Asia, and Rest of Asia Pacific
∆ South America: Brazil, Argentina, and Rest of Latin America
∆ Middle East & Africa: GCC Countries, South Africa, and Rest of Middle East & Africa

Frequently Asked Questions (FAQs):

► What is the current market scenario?
► What was the historical demand scenario, and forecast outlook from 2023 to 2030?
► What are the key market dynamics influencing growth in the Global RNAi Therapeutics Market?
► Who are the prominent players in the Global RNAi Therapeutics Market?
► What is the consumer perspective in the Global RNAi Therapeutics Market?
► What are the key demand-side and supply-side trends in the Global RNAi Therapeutics Market?
► What are the largest and the fastest growing geographies?
► Which segment dominated and which segment is expected to grow fastest?
► What was the COVID-19 impact on the Global RNAi Therapeutics Market?

Explore in-depth industry research reports across various verticals from Congruence Market Insights @ https://www.congruencemarketinsights.com/reports/all-industries

Related Reports;

► Long Read Sequencing Market: https://www.congruencemarketinsights.com/report/long-read-sequencing-market

► DNA Nanotechnology Market: https://www.congruencemarketinsights.com/report/dna-nanotechnology-market

Contact Us:

Ms. Shalaka Dubey
Senior Sales Manager
Congruence Market Insights
Palo Alto, CA 94301, United States
Phone: +1 650-646-2623
Email: sales@congruencemarketinsights.com

About Us:

Congruence Market Insights is a leading market research firm dedicated to providing in-depth analysis and strategic solutions for businesses across diverse industries. With a focus on delivering actionable insights, we offer comprehensive market intelligence, trend analysis, and forecasting to empower informed decision-making. We have built a reputation for delivering practical insights and genuine reports across diverse sectors such as biotechnology, pharmaceuticals, healthcare, technology, and more, covering an extensive array of both primary and niche sub-domains. Our expertise lies in uncovering market trends, consumer behavior, and competitive landscapes, enabling our clients to stay ahead in an ever-evolving business landscape.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNAi Therapeutics Market Worth USD 20.35 Bn by 2030 | Quark Software, Roche, Rexahn, Silence Therapeutics here

News-ID: 3392470 • Views:

More Releases from Congruence Market Insights

Construction 4.0 Market Worth USD 45.66 Billion by 2030 | Advanced Opto-Mechanical Systems, Autodesk, Trimble
Construction 4.0 Market Worth USD 45.66 Billion by 2030 | Advanced Opto-Mechanic …
The latest report by Congruence Market Insights, titled 'Global Construction 4.0 Market - Size, Trends, Share, Growth, Dynamics, Competition, and Opportunity Forecast, 2023 - 2030,' offers an in-depth analysis of the global construction 4.0 market. This report meticulously examines both macro and micro trends, providing insights into factors influencing market dynamics. It delves into qualitative and quantitative aspects, offering a precise depiction of market size, growth rates, annual progression, prevailing
Biodegradable Engine Oil Market Set to Surpass USD 1,252.4 Million by 2030 | Castrol, BP, TotalEnergies
Biodegradable Engine Oil Market Set to Surpass USD 1,252.4 Million by 2030 | Cas …
The latest report by Congruence Market Insights, titled 'Global Biodegradable Engine Oil Market - Size, Trends, Share, Growth, Dynamics, Competition, and Opportunity Forecast, 2023 - 2030,' offers an in-depth analysis of the global biodegradable engine oil market. This report meticulously examines both macro and micro trends, providing insights into factors influencing market dynamics. It delves into qualitative and quantitative aspects, offering a precise depiction of market size, growth rates, annual
Cardiac Biomarkers Testing Market Predicted to Reach USD 36.69 Billion by 2030 | Roche, Abbott, Siemens
Cardiac Biomarkers Testing Market Predicted to Reach USD 36.69 Billion by 2030 | …
The latest report by Congruence Market Insights, titled 'Global Cardiac Biomarkers Testing Market - Size, Trends, Share, Growth, Dynamics, Competition, and Opportunity Forecast, 2023 - 2030,' provides an in-depth analysis of the global cardiac biomarkers testing market. This report meticulously examines both macro and micro trends, offering insights into factors influencing market dynamics. It delves into qualitative and quantitative aspects, presenting a precise depiction of market size, growth rates, annual
Omega 3 Prescription Drugs Market Estimated to Reach USD 2.63 Billion by 2030 | Amarin, AstraZeneca, Otsuka
Omega 3 Prescription Drugs Market Estimated to Reach USD 2.63 Billion by 2030 | …
The latest report by Congruence Market Insights, titled 'Global Omega 3 Prescription Drugs Market - Size, Trends, Share, Growth, Dynamics, Competition, and Opportunity Forecast, 2023 - 2030,' presents a comprehensive analysis of the global omega 3 prescription drugs market. This report meticulously examines both macro and micro trends, providing insights into factors influencing the market dynamics. It delves into qualitative and quantitative aspects, presenting a precise depiction of market size,

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and